A Phase Ib, Open-Label Study Evaluating the Safety and Pharmacokinetics of Atezolizumab (Anti-PD-L1 Antibody) Administered in Combination With Hu5F9-G4 to Patients With Relapsed and/or Refractory Acute Myeloid Leukemia
The Phase Ib study evaluating the combination of Atezolizumab and Hu5F9-G4 in relapsed or refractory acute myeloid leukemia (AML) was terminated by Hoffmann-La Roche due to the decision to discontinue development for this indication. This outcome suggests potential challenges in the therapeutic efficacy or safety profile of the combination therapy in this patient population. The AML market remains competitive with several emerging therapies, including other immunotherapies and targeted agents. The termination of this trial may impact Roche's positioning in the AML space, necessitating a reassessment of their pipeline and strategic focus on alternative indications or combinations.
Indication: Acute Myeloid Leukemia
Modality: small molecule
Target: PD-L1 (Programmed Death-Ligand 1) and Hu5F9-G4 (anti-CD47 antibody)
Sponsor: Hoffmann-La Roche
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jul 03, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: PD-L1 (Programmed Death-Ligand 1) and Hu5F9-G4 (anti-CD47 antibody)
View original source fields
Condition raw: Acute Myeloid Leukemia
Condition normalized: Acute Myeloid Leukemia
Modality raw: small molecule
Modality normalized: small molecule
Target raw: PD-L1 (Programmed Death-Ligand 1) and Hu5F9-G4 (anti-CD47 antibody)
Target normalized: PD-L1 (Programmed Death-Ligand 1) and Hu5F9-G4 (anti-CD47 antibody)